



(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 211/40 (2006.01)
A61P 37/00 (2006.01) C07D 401/10 (2006.01)

(21) International Application Number:

PCT/US2024/010733

(22) International Filing Date:

08 January 2024 (08.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/437,951 09 January 2023 (09.01.2023) US

(71) Applicant: **MONTE ROSA THERAPEUTICS, INC.**
[US/US]; 321 Harrison Avenue, Suite 900, Boston, Massachusetts 02118 (US).


(72) Inventors: **MCALLISTER, Laura Ann**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **LIARDO, Elisa**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **RITZEN, Andreas**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **OLEINIKOVAS, Vladas**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **CABRÉ, Xavier Lu-**

cas; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **FASCHING, Bernhard**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **BIZZINI, Lorenzo Delarue**; Mattenstrasse 22, Building WRO-1055, 4058 Basel-Stadt (CH). **LESIEUR, Mathieu**; Mattenstrasse 22, Building WRO-1055, 4058 Basel-Stadt (CH).

(74) Agent: **GUTIERREZ, Gregory D.**; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: TARGETED DEGRADATION OF VAV1



(57) Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*